Chemotherapy in gastric cancer: A review and updated meta-analysis

European Journal of Surgery

Volumn 168, Issue 11, 2002, Pages 597-608

  Janunger, Karl Gunnar ^a   Hafström, Larsolof ^b   Glimelius, Bengt ^c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant; Chemotherapy; Gastric cancer; Palliative; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; META ANALYSIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH CANCER; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; PALLIATIVE CARE; POSTOPERATIVE CARE; PREOPERATIVE CARE; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0036946468     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/11024150201680005     Document Type: Article

References (129)

1. Adachi W, Koike S, Rafique M, et al. Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications. Surg Today 1995; 25: 396-403.
2. Adamo V, Scimone A, Maisano R, et al. Etoposide, 1-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother 1999; 11: 74-77.
3. Ajani JA, Mansfield PF, Lynch PM, et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999; 17: 2403-2411.
4. Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma J Natl Cancer Inst 1993; 85: 1839-1844.
5. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991; 67(1 Suppl): 260-265.
6. Ajani JA, Roth JA, Putnam JB, et al. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer 1995; 31A: 665-670.
7. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1989; 1: 571-574.
8. Atiq OT, Kelsen DP, Shiu MH, et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 1993; 11: 425-433.
9. Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996; 83: 726-733.
10. Baker LH, Talley RW, Matter R, et al. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. Cancer 1976; 38: 1-7.
11. Bergh J, Jönsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40: 253-281.
12. Bitran JD, Desser RK, Kosloff MF, et al. Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep 1979; 63: 2049-2051.
13. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-323.
14. Bonatsos C, Aust J, Meisner D, Poiesz B, Comis R. Preoperative chemotherapy for patients with locally advanced gastric carcinoma. Proceedings of the American Society of Clinical Oncology 1985; 4: 83.
15. Bresciani C, Gama-Rodrigues J, Strassmann V, Waitzberg DL, Matsuda M, Pinotti HW. Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study. Rev Hosp Clin Fac Med Sao Paulo 2000; 55: 129-136.
16. Burch PA, Keppen MD, Schroeder G, et al. North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy. Am J Clin Oncol 1999; 22: 505-508.
17. Cascinu S, Labianca R, Graziano F, et al. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1998; 78: 390-393.
18. Chou FF, Sheen Chen SM, Liu PP, Chen FC. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. J Surg Oncol 1994; 57: 239-242.
19. Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815.
20. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med 1987; 6: 245-254.
21. Coombes RC, Chilvers CE, Amadori D, et al. Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Ann Oncol 1994; 5: 33-6.
22. Crookes P, Leichman CG, Leichman L, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 1997; 79: 1767-1775.
23. Dixon WJ, Longmire WPJr, Holden WD. Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten year follow-up. Ann Surg 1971; 173: 26-39.
24. Ducreux M, Nordlinger B, Ychou M, et al. Resected gastric adenocarcinoma: randomized trial of adjuvant chemotherapy with 5 FU-Cisplatin (FUP). Final results of the FFCD 8801 trial. Proceedings of the American Society of Clinical Oncology 2000, 19: 932.
25. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-1064.
26. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
27. Engstrom PF, Lavin PT, Douglass HO Jr, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985; 55: 1868-1873.
28. Estape J, Grau JJ, Alcobendas F, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991; 213: 219-221.
29. Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993;19:29-44.
30. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-616.
31. Fink U, Schuhmacher C, Stein HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995; 82: 1248-1252.
32. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 43: 1488-1492.
33. Frasci G, Iaffaioli RV, Comella G, et al. Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement. Clin Oncol R Coll Radiol 1994; 6: 364-370.
34. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-534.
35. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994; 18: 150-155.
36. Gallardo-Rincon D, Onate-Ocana LF, Calderillo-Ruiz G. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 2000; 7: 45-50.
37. Glimelius B. Oncology in the Nordic countries - the role of Acta Oncologica? Acta Oncol 2002; 41: 3-5.
38. Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types - Summary and conclusions. Acta Oncol 2001; 40: 135-154.
39. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
40. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-274.
41. Grau JJ, Estapé J, Alcobendas F, Pera C. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993; 29A: 340-342.
42. Gunduz N, Fisher B. Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39: 3861-3865.
43. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-1312.
44. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994; 73: 2048-2052.
45. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447.
46. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group Report. Cancer 1983; 52: 1105-1112.
47. Huguier M, Destroyes JP, Baschet C, Henand F, Bernard PF. Gastric carcinoma treated by chemotherapy after resection. Am J Surg 1980; 139: 197-199.
48. Ikeguchi M, Kondou A, Oka A, Tsujitani S, Maeta M, Kaibara N. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995; 161: 581-586.
49. Imada T, Sairenji M, Suda T, Yamamoto Y, Amano T, Motohashi H. A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer. Hepatogastroenterology 1999; 46: 594-600.
50. Janunger KG, Hafström L, Nygren P, Glimelius B. For the SBU group. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309-326.
51. Jakesz R, Dittrich C, Funovics J, et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res 1988; 110: 44-51.
52. Jones AL, Trott P, Cunningham D, et al. A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol 1994; 5: 123-126.
53. Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996; 14: 1818-1828.
54. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K, Toge T. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 1999; 15: 921-926.
55. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818.
56. Koizumi W, Tanabe S, Kurihara M, Kondou I, Yamazaki I, Saigenji K. Pilot study of combined treatment with continuous infusion of 5-fluorouracil, mitomycin C, and cisplatin (FMP) in patients with inoperable advanced gastric cancer. Oncol Rep 1999; 6: 643-646.
57. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83: 458-462.
58. Kondo K, Sakamoto J, Nakazato H, et al. A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer. Oncol Rep 2000; 7: 485-490.
59. Kretzschmar A, Reichardt P, Thuss-Ptience PC, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Oncol 2000; 59: 14-17.
60. Krook JE, O'Connell MJ, Wieand HS, et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-2458.
61. Leichman L, Silberman H, Leichman CG, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 1992; 10: 1933-1942.
62. Lepage E: Meta-analysis: methodology, biostatistic rules, application in onco-hematology. Nouv Rev Fr Hematol 1989; 31: 89-91.
63. Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 1986; 4: 1348-1355.
64. Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763.
65. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308.
66. Macdonald JS, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494.
67. MacDonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533-536.
68. MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 72-30.
69. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-843.
70. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11: 418-425.
71. Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000; 23: 341-344.
72. McCulloch P, Taggart T, Ochiai A, O'Dowd G, Nash J, Sasako M. c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Surg Oncol 1997; 23: 304-309.
73. McCulloch PG, Ochiai A, O'Dowd GM, Nash JR, Sasako M, Hirohashi S. Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 1995; 75: 920-925.
74. Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 1996; 74: 1651-1654.
75. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
76. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999; 22: 580-586.
77. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
78. Nakajima T, Fukami A, Tagaki K, Kajitani T. Adjuvant chemotherapy with mitomycin C and with a multi-drug combination of mitomycin-C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J Clin Oncol 1980; 10: 187-194.
79. Nakajima T, Fukami A, Ohashi I, Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 1978; 16: 209-216.
80. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999; 354: 273-277.
81. Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984; 2: 1366-1371.
82. Neri B, de Leonardis V, Romano S, et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996; 73: 549-552.
83. Noh SH, Yoo CH, Chung HC, et al. Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. Oncology 2001; 60: 24-30.
84. Nomura E, Niki M, Fujii K, et al. Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 2001; 4: 7-2.
85. Novik Y, Ryan LM, Haller DG, Asbury R, Dutcher JP, Schutt A. Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282. Med Oncol 1999; 16: 261-266.
86. Nygren P. What is chemotherapy? Acta Oncol 2001; 40: 166-174.
87. Nygren P, Glimelius B. The Swedish Council on Technology Assessment in Health Care (SBU) report on cancer chemotherapy - Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol 2001; 40: 155-165.
88. Philip PA, Rustin GJ, Ledermann JA, Begent RH, Newlands ES, Bagshawe KD. Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinoma. Clin Oncol (R Coll Radiol) 1991; 3: 214-216.
89. Plukker JT, Mulder NH, Sleijer DTH, et al. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991; 78: 955-958.
90. Plukker JT, Sleijfer DT, Verschueren RC, Van der Graaf WT, Mulder NH. Neo- adjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and the lower oesophagus: a phase II study. Anticancer Res 1995; 15: 2357-2361.
91. Popov I, Jelic S, Radulovic S, Radosavljevic D, Nikolic-Tomasevic Z. Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: a prospective randomised trial. Ann Oncol 2000; 11: 343-8.
92. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
93. Ragnhammar P, Brorsson B, Nygren P, Glimelius B. A prospective study of use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol 2001; 40: 391-411.
94. Ravaud A, Borner M, Schellens JH, et al. UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. Oncology (Huntingt) 1999; 13 (suppl 3): 61-63.
95. Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47-51.
96. Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16: 2733-2738.
97. Ross P, Cunningham D, Scarffe H, et al. Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. Proceedings of the American Society of Clinical Oncology 1999; 18: 1042.
98. Roth A, Kolaric K, Zupanc D, Oresic V, Roth A, Ebling Z. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori 1999; 85: 234-238.
99. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000: 11: 301-306.
100. Rougier P, Mahjoubi M, Lasser P, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma -a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A: 1269-1275.
101. Safran H, Wanebo HJ, Hesketh PJ, et al. Paclitaxel and concurrent radiation for gastric cancer. Int J Radiat Oncol Biol Phys 2000; 46: 889-894.
102. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974.
103. Schiessel R, Funovics J, Schick G, et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: Results of a randomized trial. Acta Med Austriaca 1989; 16: 68-69.
104. Schlag P, Schreml W, Gaus W, et al. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res 1982; 80: 277-283.
105. Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969; 24: 223-228.
106. Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002; 52: 283-293.
107. Songun I, Keizer HJ, Hermans J, et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. Dutch Gastric Cancer Group (DGCG), Eur J Cancer. 1999; 35: 558-562.
108. Takahashi T, Hagiwara A, Shimotsuma M, Sawai K, Yamaguchi T. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg 1995; 19: 565-569.
109. The Gastrointestinal Tumor study Group. (GITSG). A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer 1982; 49: 1362-1366.
110. The Gastrointestinal Tumor Study Group. (GITSG). Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1984; 53: 13-17.
111. The Italian Gastrointestinal Tumor Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988; 75: 1100-1104.
112. Tierney GM, Griffin NR, Stuart RC, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999; 35: 563-568.
113. Tsavaris N, Tentas K, Kosmidis P, et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 1996; 42: 220-226.
114. Tsujitani S, Watanabe A, Abe Y, Maehara Y, Sugimachi K, Kaibara N. Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer. Anticancer Res 1993; 13: 2497-2499.
115. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastic cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
116. Wang XL, Wu GX, Zhang MD, Guo M, Zhang H, Sun XF. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol Rep 2000; 7: 241-244.
117. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80: 269-272.
118. Webb A, Cunningham D, Scarffe JH, Harper, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
119. Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-1326.
120. Wilke H, Preusser P, Fink U, et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer - a phase 11 study in elderly patients or patients with cardiac risk. Invest New Drugs 1990; 8: 65-70.
121. Wilke H, Stahl M, Fink U, Meyer HJ, Siewert JR. Preoperative chemotherapy for unresectable gastric cancer. World J Surg 1995; 19: 210-215.
122. Wils J, Bleiberg H, Dalesio O, et al. An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate (MTX) and 5-fluorouracil (F), combined with adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 1986; 4: 1799-1803.
123. Wils JA, Klein HO, Wagener DJT, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advance gastric cancer: a trial the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-831.
124. Wisbeck W, Becker E, Russell A, et al. Adenocarcinoma of the stomach: Autopsy observations with therapeutical implications for the radiation oncologist. Radiother Oncol 1986; 7: 13-18.
125. Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm Res 1998; 15: 517-24.
126. Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993; 17: 256-261.
127. Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996; 119: 437-444.
128. Yonemura Y, Ninomiya I, Kaji M, et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 1995; 19: 450-454.
129. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347-354.